X% Fourth on Diversified with On a same basis. up and a thanks quarter Health, Thanks, up segments, on International, a X% X% year, the basis revenue on for and Solta for consolidated basis the an organic was basis the basis with consolidated Bausch for of million Tom. billion, X% Health a with basis last excluding revenues $X.XX and line reported of quarter the closed B&L, over year. everyone, of X% full Health, fourth on on us.
We XXXX. both at the reported Hello, or year in and revenues $X.XX and quarter basis, an reported last reported X% were and a Bausch our organic organic joining Salix an growth compared XX% to over on ended same basis excluding year.
Bausch organic billion, while increased year $X.XX quarter last billion, $XXX on B&L, up in revenues
more including reported in detail, for into revenue on dive each increased and starting by the $X in Trulance. TRx prior key $XXX and the wholesaler Comparisons Let's Xifaxan, on Slide products, million, Salix driven an to Salix. million organic changes patterns. impacted quarter our basis growth of to performance in with quarter both by buying were the Fourth year's segment XX Relistor revenues timing
reported compared XXXX growth will XX% the to XXXX. quarter of the quarter in third recall, sales you As of third
an inventory QX this had saw the we noted in saw XXXX. And earlier in QX As in build anticipated. then, wholesale we quarter, to a compared in than decline we inventory channel wholesale channel increase we of
increase overall $X.XX and an full approximately impact split demand increase We the levels X% on approximately an inventory billion, realized For along increase of volume, an net roughly of over approximately year-over-year. a higher X% X% in Salix wholesale reported volume underlying of between year, reported increase the with revenues price with equally in the XXXX basis.
relative in While year Salix this IBS-D importantly, than prescriptions units approximately X.X% in outpatient channel did for solid and represent XXXX.
Xifaxan segment strong growth we higher channel revenues the versus saw QX TRx in the end QX in quarter. TRx QX, to X% we and inventory continued growth year-over-year clinics. saw in demand. grew XX% in nonretail for Retail in declined strong saw ended approximately to We also growth care underlying to year as the of the prior long-term well as attributable growth we of
wholesaler the buying prior Xifaxan offset TRx discussed line quarter, the patterns of revenues year in by earlier. the timing with For was growth were as the
quarter, performances Relistor and offset was $XXX compared basis million basis Trulance the on TRx shifts reported and were in were the year organic demand revenues Latin delivered increase both X% America over and growth year quarter, lower the pricing and prior the strong EMEA, XX% the wholesale due improved higher as net period, on revenues during Canada net across prior pricing, an For inventory.
International a XX% while to an flat, growth by to of with regions.
$XXX performance the X% were to billion $X.XX pricing, year's recall mainly effects quarter. organic an X% For basis. year, million International on impact as driven our by was an increase the full by offset million basis increased and second reported of International the for realized compared a $XX and of of XXXX, in on in the the competition growth segment was products This of revenues XXXX net an Emerade or for in promoted portfolio generic increase
over Solta of period. basis Medical sales to an Asia a while the U.S. year. and prior by $XXX to quarter the were lesser million for led on declined China compared revenues the quarter, X% Growth organic fourth slightly Pacific, and increase reported year the prior remainder basis X% degree, the of on in an in the was a
this China, a the the demand to revenues fourth COVID-related the were of basis from of including reported the by as business an is approximately as FLX near- of Medical was important EMEA, lockdowns.
With increase long-term the possible we lesser bring of by Solta in U.S. period. market in revenues mentioned, year-over-year X% in for affected in organic in patients with continued year Thermage the during constraints products and net basis business. on $XXX the of for $XXX addition we as capitalize to a by launched an growth, ended quarter, January benefits competing is pricing growth Tom Arazlo on by And nonpromoted were a a to continues the XX% organic to pressures this quarter products.
And for XX% return potential Medical our coming by the opportunities comparison reported to in the driven million the declined believe positioned increase XXXX. recent we and China Pacific China, business degree, Solta globally.
Diversified increases Asia offset cash-generative opportunity to be XXXX. on for created is were revenue and X% and quarter.
In among strong growth.
The pressure an region prior compared the XXXX to revenue approval supply on an Generics to and CABTREO untapped consumables, growth year rest delivered dermatology and available relative view the of for Revenue product and this as Jublia an and and on business continue compared Dermatology, million, of patients, XX% to late year Neurology to basis fourth in continued to on the XX% volume effect basis expected continued the profitable, as prior
a faces standpoint. pricing highly a both volume environment it also competitive However, from and
our While of term, competitive LOEs million and of and LOE revenue in $XX recorded impairment our we for products, with revised many in quarter with of the business the have for long we expectations of quarter.
Dentistry $XX environment expect fourth million in role line a this time line an face XXXX. strong it goodwill with plays the a to was those of the
the invest XXXX. term accelerate and to growth in are the for to continue looking We long in Dentistry business
the with Diversified we've declines basis a the in on revenues dermatology the declined degrees organic year, year, X% X% reflecting the pressures discussed relative year. an generics basis and segment For neurology, on of throughout and varying to prior reported
X% Lomb basis for a or XXXX. all and by Lomb to Bausch year revenues basis the $X.XX increased reported with compared basis basis an billion Slide As on shown and during year, + revenues XX% XX, on quarter, the segments. across organic XX% organic Bausch on Bausch X% up compared on + the to Lomb Similarly, were reported + an growth on fourth prior million a $XXX
year. on consolidated points points gross was margin XX%, last compared and Turning XXX adjusted Fourth higher prior gross year. was basis fourth year margin XX.X%, higher than consolidated XX the basis quarter with to adjusted the XX Full Slides XX. quarter P&L
For last points fourth quarter B&L, than the quarter. margin XX.X%, Bausch basis Health, excluding year's for was XX adjusted fourth gross lower approximately
$XXX year, margin basis full was gross XX.X% impact QX mix, quarter primarily the for adjusted product points, expenses the increase the to XX.X% of of margin Emerade gross of operating the by For adjusted driven year.
At QX earlier in million. of recall for an 'XX a adjusted for were XX including fourth Xiidra.
Consolidated was which included decline compared XX.X%, of the $XXX B&L, XXXX, million,
on year reported and of $XX for as for increased X.X% structure approximately related also of expenses quarter, favorable by operating R&D stabilization A&P, excluding period. increased prior Bausch our Health, came adjusted post-IPO the the the investments quarter prior A&P to during launches.
Consolidated X% Salix containment. focused prior B&L, an Salix B&L, to product selling increased primarily Health, in primarily by was and expense an and G&A with slightly the to For the segment.
R&D million was initiatives. by increase expenses represented operating compared Bausch the million to $XXX for due we adjusted of driven Adjusted annualized of as was adjusted the cost higher B&L $XXX expenses driven year, product excluding sales increase year million, X.X%
For Bausch as Health, excluding compared the fourth same quarter year. by the of for increased approximately B&L, quarter R&D million last million expenses $XX to $X
to mentioned, throughout of support in expect for As R&D another step-up next Tom the XXXX Amiselimod. development phase we meaningful expense
for increase slight continue million $XX was $XXX X was the quarter XXXX. quarter from X% Bausch or excluding also $XXX RED-C $XXX B&L, EBITDA million the an on of We EBITDA million trials.
Fourth a basis. adjusted progress will a Adjusted of III in Health, global to consolidated fourth million, increase clinical quarter, for our Phase reported
was billion, and the $X.XX excluding Bausch from adjusted billion increases year, EBITDA For both Health, slight was $X.XX for B&L, full 'XX. consolidated
was consolidated a fourth a on cash operating On flow cash Bausch operating basis, operations flow. from basis year $X.XX from adjusted of cash and of the in million $XXX cash to cash quarter. $XXX Full $XXX million. Health flow million a on generated was flow adjusted Turning consolidated consolidated billion basis and flow operations
management reflecting $XXX cash I million the the and million primarily based for of $XXX XXXX the interest movements operating and quarter flow cash wholesaler excluding operating full QX, the B&L, quarter year to payments.
The $XXX timing with capital million of buying and changes on was the $XXX year the the our exceeded the adjusted year for cash compared flow For full for $XXX timing 'XX Bausch guidance working patterns also full of earlier. fourth expense Health, of for million focus fourth by XXXX, million, as well by of on driven our timing discussed collections as for the of adjusted
result interest portion the payments matters, as proceeds. discussed flows. payment costs of of we've debt other a cash prior payments accounting our as a the are full XXXX financing our issued Adjusted of business of interest the in as as exchange, adjustments and for part cash contractual As senior well for treatment the notes quarters, classified as separation includes transformation net flow costs, and cash of litigation of insurance
our Now XX. Slide balance let's sheet to on turn
B&L, We we to fourth Health, continued $XXX debt XXXX, the prioritize cash Bausch million. of delevering of our liquidity quarter of excluding management the In approximately sheet. net reduced balance for by and our
revolving market We continue focusing despite evaluate leverage while in on through of value repurchases, the capturing debt our facility. a outstanding XXXX, to outstanding $XXX reduce our million approximately we retiring XXXX XXXX borrowings our also Bausch no fourth Health, credit in January open and approximately profile million small principal retired under excluding our amount availability QX.
In and maturities in million had end discount facility only the $XXX maturity At of B&L, of overall process. quarter, alternatives and million to receivable $XX of accounts of under had the $XXX
$XX receivable the billion shown Lomb, was issued excluding created $X.X the As of Health, for unrestricted includes consisted Bausch the by of secured in and debt, subsidiary by $X Health, and issued third restricted unrestricted excluding Slides total B&L, notes our the of Bausch senior accounts of which facility. under and billion XXXX of at approximately billion debt million Bausch $XXX quarter XX billion, the drawn debt of + on the $XX.X which end approximately quarter XX,
approximately XX% of $XXX is over revolving the XX% our of fixed basis approximately million a approximately consolidated since our facility. of cash excluding Excluding for of ended company's is credit with down million cash of million on of and is XXXX.
We $XXX debt under net the year billion including fixed. B&L, liquidity, of $XXX Health, $X.X debt the Bausch availability approximately beginning and debt, Debt, B&L
or We to will exceeded expectations.
With that with and can excluding overall as of B&L, an basis. uses for best the and the expect X% revenues, backdrop, for I'll now Slide EBITDA maturity our evaluate which to XXXX, Bausch flow that to we for $X.XX on we including XXXX, continue XX.
In liquidity, discuss that our of operating Health, on focus X% pleased billion cash adjusted growth our XXXX are revenues leverage.
Overall, you profile adjusted $X.X on guidance organic billion, find of met
impact be slight Health, tailwind. to for Bausch be year excluding For $X.XX a exchange expect is adjusted XXXX, B&L, foreign to to we expected $X.XX Full EBITDA billion billion.
relative how into what expect we Salix, from made, we've we extended the saw volume wholesaler to although see in dynamics on to and TRx expect unit growth revenue changes temper mid-single-digit growth may to translates a we that expand investments Based XXXX, growth. growth. For revenue purchasing perspective in
also levels. We A&P selling to our XXXX with maintain in consistent and intend investments
as well typically noted the dynamics deductible we've insurance the in inventory due past, seasonal patterns level to see particularly second wholesaler to as a half, step-up in Xifaxan, activity. in sales as patient related we primarily Lastly, in
and America EMEA Latin For regions. organic expect by led International, we growth, mid-single-digit the revenue
recently new to targeted products, we of different the by across and in Canada, for further Ryaltris launched In excited the CABTREO. approval regions. obtaining grow potential these plan are to regions. product also sales continue teams in the on and launches promotion investments and focus making We're We Uceris
growth double-digit we geographies. strong all organic revenue Solta, anticipate across For major
and leaders we Asia in Pacific new U.S. have expansion double-digit well team. business as growth U.S. of as in by have in Therefore, invested regions. sales led the and and in this EMEA the China growth We positions key anticipate
mid-single-digit For in organic an revenue. Diversified, overall decline we expect
with related expect We investment in a by force the continued tools, driven in led inflation gross our generics year the businesses.
From and and margin Dentistry sales and on CABTREO last perspective, in introduction the to and of margin gross continued in expect mitigate sold, neurology pressures to at growth remain by to XX%. to we of cost approximately of goods we our continue expect impact comparable Dermatology our
will drive and we On targeted we growth and anticipate that as line in sales businesses, Dentistry. the to we and make expense in grow Solta maintain the A&P selling XXXX growth, in including side, established investments base with
it as increase is we've in discussed GI and a area we will will in it and there while to as pipeline year, to Additionally, long our to We spend invest care stakeholder the allocate term, the meaningful throughout future for our be capital patients deliver health this critical value. the to previously, R&D continue programs. for providers benefit think as positioning aesthetics business
the of back the of Tom. said earlier, contractual our cash adjustments relative to the on includes also inclusive payment Lastly, XXXX. for of to And in the lower I Bausch adjusted adjusted cash XXXX, interest flow we full the Settlement.
I'll $XXX expect hand XXXX flow includes to payment separation operating tentative and for Health, tax approximately $XXX Trust million now as payments of debt for call Granite in excluding costs. existing B&L, a the impact range million of
